← Browse by Condition
Medical Condition

leiomyosarcoma

Total Trials
4
Recruiting Now
4
Trial Phases
Phase 2

ClinicalMetric tracks all active clinical trials for leiomyosarcoma sourced from ClinicalTrials.gov. Research in this area spans early-phase safety investigations through large Phase 3 confirmatory trials, conducted by NIH-funded academic centers, independent investigators, and pharmaceutical sponsors worldwide. Each listing is updated daily as new studies open enrollment and existing ones reach capacity or complete follow-up.

Trial listings include the NCT identifier, current recruitment status, phase classification, primary and secondary endpoints, estimated enrollment size, participating countries, and direct links to the full protocol on ClinicalTrials.gov. Eligibility criteria — including age range, disease stage, and prior treatment requirements — are documented for every study to help patients and clinicians assess suitability before contacting a trial site.

Frequently Asked Questions — leiomyosarcoma Clinical Trials

How many clinical trials are currently recruiting for leiomyosarcoma?
ClinicalMetric currently tracks 4 actively recruiting clinical trials for leiomyosarcoma, sourced in real time from ClinicalTrials.gov. The total number of registered studies—including those not yet enrolling or in active follow-up—is 4. Trial availability changes daily as new studies open enrollment and existing ones reach capacity.
What trial phases are available for leiomyosarcoma?
leiomyosarcoma research spans Phase 2 (1 trial). Phase 1 studies evaluate safety and dosing in small groups, Phase 2 studies assess preliminary efficacy in 100–300 participants, and Phase 3 trials compare the new treatment against the standard of care in 300–3,000+ patients. Phase 4 post-approval studies monitor long-term outcomes in real-world populations.
How do I find out if I qualify for a leiomyosarcoma clinical trial?
Eligibility criteria for leiomyosarcoma trials vary by study and typically specify age range, disease stage or severity, prior treatment history, and specific diagnostic or laboratory parameters. Each listing on ClinicalMetric links to the full protocol on ClinicalTrials.gov, where inclusion and exclusion criteria are documented. Contact the sponsoring site's research coordinator directly to confirm your eligibility—your treating physician or specialist can also help identify the most appropriate trial based on your medical history and current treatment status.
Trial Phases
Phase 2
1
Top Sponsors
Sanford Health 1 trial
University of Michigan Rogel Cancer Center 1 trial
Centre Leon Berard 1 trial
HRYZ Biotech Co. 1 trial

Recruiting Clinical Trials

NCT01793168
Recruiting
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Enrollment
20,000 pts
Location
United States
Sponsor
Sanford Health
View Trial →
NCT05653388
Recruiting
Metastatic Leiomyosarcoma Biomarker Protocol
Enrollment
200 pts
Location
United States, Austr...
Sponsor
University of Michigan Rogel C...
View Trial →
NCT04055220
Recruiting
Efficacy and Safety of Regorafenib as Maintenance Therapy After First-line Treatment in Patients With Bone Sarcomas
Enrollment
168 pts
Location
France
Sponsor
Centre Leon Berard
View Trial →
NCT06277154 Phase 2
Recruiting
MASCT-I Combined With Doxorubicin and Ifosfamide for First-line Treatment of Advanced Soft Tissue Sarcoma
Enrollment
148 pts
Location
China
Sponsor
HRYZ Biotech Co.
View Trial →

Related Conditions

beta mannosidosis (2) undifferentiated pleomorphic sarcoma (2) angiosarcoma (2) rare disorders (1) undiagnosed disorders (1) disorders of unknown prevalence (1) cornelia de lange syndrome (1) prenatal benign hypophosphatasia (1) perinatal lethal hypophosphatasia (1) odontohypophosphatasia (1) adult hypophosphatasia (1) childhood onset hypophosphatasia (1)
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: November 2026  ·  Data Methodology